Abstract: The invention relates to once a day pharmaceutical compositions comprising a fixed dose combination of a ?? blocker or a pharmaceutically acceptable salt or ester thereof and an SGLT2 inhibitor or a pharmaceutically acceptable salt or ester thereof with one or more pharmaceutically acceptable excipients. In addition the present invention also relates to use of such pharmaceutical compositions in patients for the prevention or treatment of heart failure with reduced ejection fraction (HFrEF) with and without Type 2 diabetes angina myocardial infarction arteriosclerosis diabetic nephropathy diabetic cardiac myopathy renal insufficiency peripheral vascular disease left ventricular hypertrophy cognitive dysfunction and chronic heart failure.
| # | Name | Date |
|---|---|---|
| 1 | 202427070102-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [17-09-2024(online)].pdf | 2024-09-17 |
| 2 | 202427070102-STATEMENT OF UNDERTAKING (FORM 3) [17-09-2024(online)].pdf | 2024-09-17 |
| 3 | 202427070102-REQUEST FOR EXAMINATION (FORM-18) [17-09-2024(online)].pdf | 2024-09-17 |
| 4 | 202427070102-PRIORITY DOCUMENTS [17-09-2024(online)].pdf | 2024-09-17 |
| 5 | 202427070102-POWER OF AUTHORITY [17-09-2024(online)].pdf | 2024-09-17 |
| 6 | 202427070102-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [17-09-2024(online)].pdf | 2024-09-17 |
| 7 | 202427070102-FORM 18 [17-09-2024(online)].pdf | 2024-09-17 |
| 8 | 202427070102-FORM 1 [17-09-2024(online)].pdf | 2024-09-17 |
| 9 | 202427070102-FIGURE OF ABSTRACT [17-09-2024(online)].pdf | 2024-09-17 |
| 10 | 202427070102-DECLARATION OF INVENTORSHIP (FORM 5) [17-09-2024(online)].pdf | 2024-09-17 |
| 11 | 202427070102-COMPLETE SPECIFICATION [17-09-2024(online)].pdf | 2024-09-17 |
| 12 | 202427070102-ORIGINAL UR 6(1A) FORM 26-281024.pdf | 2024-11-04 |
| 13 | 202427070102-Proof of Right [03-12-2024(online)].pdf | 2024-12-03 |
| 14 | 202427070102-ORIGINAL UR 6(1A) FORM 1-091224.pdf | 2024-12-24 |